PureTech Health is a biotherapeutics company that operates a hub-and-spoke model to identify and advance therapeutic candidates with validated pharmacology. The company scales innovations through Founded Entities, which are spun out with external capital to accelerate their path to patients. Its portfolio includes multiple clinical-stage programs across areas of significant patient need, focusing on enhancing on-target efficacy, enabling oral administration, or improving tolerability. Notable Founded Entities include Seaport Therapeutics, which is developing GlyphAgo for conditions such as generalized anxiety disorder and sleep disturbance. The company has a track record of creating dozens of therapeutic candidates, including three that have received U.S. Food and Drug Administration approval.

Summarised from the company's own disclosures, fiscal year ended Dec 2025

Industry Biotechnology Homepage puretechhealth.com
Sector Healthcare IR page investors.puretechhealth.com/events-presentations
Tags
biotherapeutics, clinical-stage, hub-and-spoke, founded entities, neuroscience, anxiety disorders, sleep disorders, drug discovery, Seaport Therapeutics, GlyphAgo
Press page —

Metrics

Valuation  
Market cap £ 288.884M
Market cap (USD) $ 382.932M
P/E -3.45
PEG —
P/BV 1.02
P/S 82.77
P/OCF -4.53
P/FCF -4.53
Dividend yield —
Turnover / mcap —
Returns  
ROE -30.9%
ROI -171.2%
ROIC -114.9%
Profit margin -2,362.8%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -50.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 4.659M 4.828M 3.33M 15.618M 17.388M 11.768M 9.807M 20.748M 650K 333K 11.828M 2.222M
Net profit -110.084M 27.782M -66.628M -37.065M -62.709M 4.568M — -70.659M -70.697M -2.434M — —
Free cash flow -85.137M -134.38M -105.987M -180.968M -163.845M -136.997M — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 1.67 3.25 — 3 4 — — — — — — —
Price performance 12m -0.5 — — -0.12 — — — — — — — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 2.56M 3.17M 11.9M 2.38M 1.52M 1.76M
↳ YoY growth +24.1% +273.9% -80.0% -35.9% +15.5%
↳ 5y CAGR -7.2%
Borrowings, current (USD) — — 0.00 857,000 5.16M 0.00 — —
Borrowings, non-current (USD) — — 14.8M 14.3M 10.2M 0.00 — —
Lease liabilities (USD) — — 35.3M 33M 29.1M 21.6M 18.3M 14.7M
Cash and deposits (USD) 117M 132M 404M 466M 150M 191M 281M 252M
Intangible assets (USD) — — 899,000 987,000 831,000 906,000 601,000 601,000
Right-of-use assets (USD) — — 20.1M 17.2M 14.3M 9.83M 8.06M 6.3M
Net debt (borrowings + leases - cash) (USD) — — -354M -418M -105M -169M — —
Cash flow detail
Operating cash flow (USD) — -98.2M -132M -158M -179M -106M -134M -85.1M
Purchases of property, plant and equipment (USD) — -12.1M -5.17M -5.57M -2.18M -70,000 -11,000 -6,000
Purchases of intangible assets (USD) — -400,000 -254,000 -90,000 0.00 -175,000 0.00 0.00
Change in receivables (cash effect) (USD) — 747,000 -529,000 -617,000 -7.73M 9.75M 629,000 -236,000
Change in payables (cash effect) (USD) — 14.2M 598,000 8.34M 22M 3.84M -9.7M -1.03M
Share buybacks (cash effect) (USD) — — — — -26.5M -19.7M -4.79M —
Interest paid (cash effect) (USD) — -2.5M -2.65M -3.38M -3.37M -1.7M -1.3M -4.52M
Income taxes paid (cash effect) (USD) — 0.00 -20.7M -27.8M -20.7M -150,000 -37.9M -5.5M
Share-based compensation (USD) — 14.5M 10.7M 14M 14.7M 4.42M 22.9M 8.22M
Operating cash flow before change in receivables (USD) — -98.9M -131M -158M -171M -116M -135M -84.9M
Free cash flow (OCF - PPE - intangibles) (USD) — -111M -137M -164M -181M -106M -134M -85.1M
Income detail
Research and development expense (USD) — 85.8M 81.9M 110M 152M 96.2M 69.5M 56.6M
↳ 5y CAGR -4.1% -7.1%
Total comprehensive income (USD) — 366M 5.04M -62.7M -37.4M -66.5M 27.8M -110M
Comprehensive income to owners (USD) — 421M 6.45M -60.6M -50.7M -65.6M 53.5M -110M
Reported Apr 26, 2022 Apr 26, 2022 Apr 26, 2022 Apr 26, 2022 Apr 28, 2023 Apr 25, 2024 Apr 30, 2025 Apr 29, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

2026-10-30

Download PDF

RNS Number : 0796B

PureTech Health PLC

30 October 2026

30 October 2026

PureTech Health plc

PureTech Health Wins 2026Prix Galien USAAward in Incubators, Accelerators and Equity Category

Recognition highlights PureTech's differentiated model for identifying and advancing medicines through the creation of dedicated biotechnology companies

PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced that it has won the 2026 Prix Galien USA Award for "Incubators, Accelerators and Equity." The award was presented at the 20th Annual Prix Galien USA Awards Ceremony on October 29, 2026, at the American Museum of Natural History in New York City. PureTech was honored for its model of identifying and de-risking therapeutic candidates and establishing dedicated companies to advance the most promising programs toward patients.

PureTech's approach is grounded in its LIFE (Launching Innovation From Existing Pharmacology) model, a systematic framework for identifying opportunities to unlock the potential of validated pharmacology, with a hub-and-spoke structure designed to advance those opportunities efficiently. As programs reach key value-inflection points, PureTech launches dedicated Founded Entities with their own leadership teams and attracts third-party investment to advance them. PureTech's approach has delivered an 80% clinical trial success rate and three FDA-approved therapeutics. Complementing this track record of clinical success, PureTech's hub-and-spoke model has enabled the creation of dedicated Founded Entities that have attracted more than $4 billion in third-party financing since 2018.

"We are honored to receive this recognition from the Galien Foundation, which is a testament to the vision and dedication of our team over more than two decades," said Robert Lyne, Chief Executive Officer of PureTech. "Our model was built on the belief that promising science deserves a path forward, even when traditional development approaches fall short. By combining our ability to unlock the potential of validated pharmacology with a model that brings together dedicated teams and external capital, we have created a portfolio spanning FDA-approved medicines, publicly traded companies, and early-stage programs. We are proud of what this approach has achieved and remain focused on translating innovative science into medicines that make a meaningful difference for patients."

About****The Galien Foundation The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve human health. Its vision is to serve as a catalyst for the development of the next generation of treatments and technologies that will transform medical practice and save lives. Established in Paris in 1970 by Roland Mehl in honor of Galen, the father of medical science and modern pharmacology, the Prix Galien is widely regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

Today, the Prix Galien operates through 18 chapters spanning more than 75 countries across Africa, the Americas, Asia, and Europe. Expansion is currently underway in China, Singapore, and Australia.

In 2025, the Foundation launched the inaugural Prix Galien Bridges Forum and Awards Ceremony at the Nobel Forum in Stockholm, spanning Northern and Southern Europe, Israel, and the Middle East, and the first-ever Patient Summit for Prix Galien USA, reinforcing its commitment to science without borders.

The Nobel Prize and the Prix Galien share a common birthplace in Paris, where Alfred Nobel signed his last will and testament in 1895. However, while the Nobel Prize in Physiology or Medicine recognizes up to three individuals for specific discoveries, the Prix Galien honors the collaborative spirit and multidisciplinary progress that define modern biopharmaceutical innovation.

2026-10-29

Download PDF

RNS Number : 9014A

PureTech Health PLC

29 October 2026

29 October 2026

PureTech Health plc

PureTech Founded Entity Celea Therapeutics Appoints Paul Audhya, MD, MBA, as Chief Medical Officer

PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Celea Therapeutics, Inc. ("Celea"), today announced the appointment of Paul Audhya, MD, MBA, as Chief Medical Officer. Dr. Audhya joins an experienced leadership team that includes Sven Dethlefs, PhD, Chief Executive Officer; Vishwas (Vish) Setia, MBA, Chief Financial Officer; Ronen Tamir, MBA, Chief Operating Officer; and David M. Stark, JD, General Counsel, Secretary and Chief Compliance Officer. Collectively, Celea's leadership team brings experience across clinical development, regulatory strategy, commercial launches, strategic transactions, financing, and organizational growth.

The full text of the announcement from Celea is as follows:

Celea Therapeutics Appoints Paul Audhya, MD, MBA, as Chief Medical Officer

Appointment strengthens Celea's leadership team as the company advances deupirfenidone through Phase 3 development in idiopathic pulmonary fibrosis (IPF)

BOSTON -- October 29, 2026 - Celea Therapeutics, Inc. ("Celea" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for serious respiratory diseases with significant unmet medical need, today announced the appointment of Paul Audhya, MD, MBA, as Chief Medical Officer. Dr. Audhya brings nearly three decades of experience in leading clinical development and global medical affairs organizations. He joins Celea's experienced leadership team and will oversee Celea's clinical development and medical strategy, including the ongoing Phase 3 SURPASS-IPF trial.

"Paul brings deep clinical development and medical affairs expertise, as well as a proven record of guiding programs from development through commercialization," said Sven Dethlefs, PhD, Chief Executive Officer of Celea. "His appointment marks an important step in building out the leadership team required for Celea's next phase of growth. Following the closing of our $180 million financing in July and Celea's spin-off from PureTech Health, we have assembled an accomplished team with deep experience in company building, clinical development, commercialization, strategic finance, and global operations. Together, we are focused on advancing deupirfenidone with the ongoing Phase 3 SURPASS-IPF trial, and building Celea into a leading respiratory disease company."

"For too long, people living with IPF have faced a difficult balance between treatment efficacy and tolerability. With deupirfenidone, we aim to move beyond that trade-off and raise the bar for efficacy in IPF," said Dr. Audhya. "Initiating the landmark Phase 3 SURPASS-IPF trial is a transformative milestone for our program. I am thrilled to join the exceptional team at Celea and eager to collaborate with our investigators, advisors, and the patient community to unlock the full potential of deupirfenidone."

Dr. Audhya most recently served as Chief Medical Officer of KalVista Pharmaceuticals, Inc., where he led global clinical development strategy and regulatory authority submissions across major international markets. He previously held senior leadership roles at Arena Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Hospira, Inc., and Reata Pharmaceuticals, Inc., and had roles of increasing responsibility at Abbott Laboratories, Amgen Inc., Bristol-Myers Squibb Company, and Janssen Pharmaceuticals, Inc., and has guided programs from development through commercialization across multiple therapeutic areas, including for rare diseases.

Building Celea's Leadership Team for its Next Phase

Dr. Audhya joins an experienced leadership team led by Chief Executive Officer Sven Dethlefs, PhD, and further strengthens the Company's executive leadership team following its spin-off from PureTech Health and the closing of the Company's $180 million financing in July 2026. The team also includes:

Vishwas (Vish) Setia, MBA, Chief Financial Officer, who previously served as Chief Financial Officer of MapLight Therapeutics, Inc., where he led the company's Series D financing and initial public offering, and previously spent a decade in healthcare investment banking at BofA Securities, Inc.

Ronen Tamir, MBA, Chief Operating Officer, who has built and scaled global organizations through leadership roles at Pfizer Inc., Teva Pharmaceutical Industries Limited, GE Healthcare, Rosetta Genomics Ltd., Novartis AG and EMD Serono Inc.

David M. Stark, JD, General Counsel, Secretary and Chief Compliance Officer, who previously served as Chief Legal Officer of Teva Pharmaceutical Industries Limited, where he led the global legal organization for nearly a decade.

Collectively, Celea's leadership team brings experience across clinical development, regulatory strategy, commercial launches, strategic transactions, financing, and organizational growth. Their experience, spanning global pharmaceutical leadership and emerging biotechnology company building, positions Celea to execute its mission with speed, discipline, and a strong focus on creating value for patients and stakeholders.

About Celea Therapeutics

Celea Therapeutics is a clinical-stage biopharmaceutical company focused on developing differentiated therapies for serious respiratory diseases with significant unmet medical need. The Company's therapeutic candidate, deupirfenidone, is an investigational next-generation oral antifibrotic therapy being evaluated in a Phase 3 clinical program for IPF, a progressive and fatal lung disease. Building on the established antifibrotic foundation of pirfenidone, deupirfenidone is being developed with the goal of improving outcomes for patients with IPF and potentially other progressive fibrotic interstitial lung diseases. Through its focus on enhancing the therapeutic benefits of antifibrotic treatment, Celea aims to advance the standard of care in fibrotic lung disease.

About PureTech Health

PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.

2026-10-26

Download PDF

RNS Number : 4056A

PureTech Health PLC

26 October 2026

26 October 2026

PureTech Health plc

PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026

Oral presentation highlights depth of responses in heavily pretreated patients with R/R HR-MDS, including two MRD-negative complete responses enabling stem cell transplantation

LYT-200 demonstrated a favorable safety profile across 101 patients with R/R HR-MDS and AML, with no dose-limiting toxicities or LYT-200-related serious adverse events

PureTech Founded Entity, Gallop Oncology, plans to advance LYT-200 into Phase 2 STRIDE-MDS trial in patients with R/R HR-MDS following successful FDA End-of-Phase 1 meeting and receipt of Fast Track designation

PureTech Healthplc(LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced that results from the Phase 1b clinical trial of LYT-200 were presented in an oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. LYT-200 is a first-in-class monoclonal antibody targeting galectin-9, an important oncogenic driver and potent immunosuppressor. It is being advanced by PureTech's Founded Entity, Gallop Oncology (Gallop).

The completed Phase 1b trial (NCT05829226) was conducted across nine U.S. sites and evaluated LYT-200 both as a monotherapy and in combination regimens across 101 heavily pretreated patients with relapsed/refractory (R/R) high-risk myelodysplastic syndromes (HR-MDS) or acute myeloid leukemia (AML). The trial included dose escalation of LYT-200 monotherapy, followed by dose escalation of LYT-200 in combination with a hypomethylating agent (HMA; azacitidine or decitabine) in patients with R/R HR-MDS and with venetoclax (VEN) and an HMA in R/R AML.

As previously disclosed, topline results showed encouraging clinical activity and favorable safety in a heavily pretreated patient population. The oral presentation at ESMO provided further detail on the depth of responses observed. In R/R HR-MDS, LYT-200 at 12 mg/kg in combination with an HMA demonstrated a 36.4% complete response + partial response rate and a 45.5% overall response rate in 11 efficacy-evaluable[1] patients, all of whom had previously received HMA therapy. Notably, two patients in this treatment cohort achieved MRD-negative complete responses and subsequently proceeded to stem cell transplantation.

Efficacy-evaluable R/R HR-MDS patients had a median of 3 prior lines of therapy (range: 1-5), and all (100%) had previously been treated with an HMA. Importantly, clinical responses were observed across patients with a range of mutations (i.e., BCOR, DNMT3A, SF3B1, TET2, PTPN11, KRAS, and RUNX1-RUNX1T1), and all patients had high-risk cytogenetics, which - coupled with prior exposure to treatment - suggests biologically aggressive, treatment-refractory disease with elevated risk of progression and poor clinical outcomes. Taken together, these attributes underscore the potential mutation-agnostic mechanism of LYT-200 and its potential for broad clinical use.

LYT-200 demonstrated a favorable and consistent safety profile across all cohorts and dose levels studied (N=101), with no dose-limiting toxicities, infusion-related reactions, LYT-200 dose reductions, or LYT-200-related serious adverse events (AEs), discontinuations, or deaths. Importantly, no overlapping or additive toxicities were observed when LYT-200 was combined with an HMA or venetoclax/HMA.

"What is particularly encouraging about these findings is the combination of clinical activity, depth of response and tolerability observed in patients who have already received multiple lines of treatment," said Guenther Koehne, MD, PhD, Deputy Director and Chief of Blood & Marrow Transplant and Hematologic Oncology at Baptist Health Herbert Wertheim Cancer Institute, who presented the Phase 1b results at ESMO. "In high-risk MDS, we need therapies that can achieve meaningful disease control without adding substantial treatment burden. These results provide an encouraging foundation for evaluating LYT-200 in a larger, randomized study and better understanding its potential role in treating this challenging disease."

Following a successful End-of-Phase 1 meeting with theU.S. Food and Drug Administration(FDA) and receipt of Fast Track designation for R/R HR-MDS, Gallop plans to advance LYT-200 into Phase 2 development. The Study of Two Regimens Investigating Dose and Efficacy of LYT‑200 in Relapsed/Refractory High-Risk MDS (STRIDE-MDS) will be a randomized, double-blind, placebo-controlled Phase 2 trial enrolling approximately 125 patients with R/R HR-MDS. Patients will be randomized 2:2:1 to receive LYT-200 at 12 mg/kg plus an HMA, LYT-200 at 7.5 mg/kg plus an HMA, or placebo plus an HMA, respectively. The trial will assess the efficacy of LYT-200 as measured by the rate of complete and partial responses to support dose selection. Gallop plans to initiate the trial after securing external capital.

About Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are a group of serious blood cancers characterized by ineffective blood cell production in the bone marrow, leading to anemia, infections, and bleeding complications.[2],[3] MDS affects approximately 60,000-170,000 people in the United States, with an estimated 30-40% of patients diagnosed with the more aggressive form of the disease known as high-risk (HR) MDS.2, [4] HR-MDS is associated with poor outcomes, with median survival typically less than two years following diagnosis.

The current standard frontline treatments for HR-MDS are hypomethylating agents (HMAs), such as azacitidine and decitabine; however, most patients do not respond to these therapies or eventually stop benefiting from them.[5] Once the disease becomes relapsed or refractory (R/R), outcomes are especially poor, with survival often limited to only a few months.5,[6]

Treatment options for patients with R/R HR-MDS remain very limited. Only one therapy has been approved by the U.S. Food and Drug Administration specifically for R/R HR-MDS in the past two decades, and it targets a genetic mutation found in only approximately 3% of patients.5 As a result, there remains a significant unmet need for treatments for the overwhelming majority of patients with R/R HR-MDS.

About LYT-200

LYT-200 is a Phase 2-ready, fully human monoclonal antibody in development for the treatment of relapsed/refractory (R/R) high-risk myelodysplastic syndromes (HR-MDS). It is the most advanced therapeutic candidate targeting galectin-9, which is an important oncogenic driver and potent immunosuppressor that plays a central role in some of the most difficult-to-treat cancers. With its mutation-agnostic, dual mechanism of action, LYT-200 is designed to address both the malignant cells and the immunosuppressive environment that sustain disease. LYT-200 has been granted Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of R/R HR-MDS in combination with a hypomethylating agent. LYT-200 has also been granted Fast Track designation from the U.S. FDA for the treatment of acute myeloid leukemia (AML).

About Gallop Oncology Gallop Oncology is a clinical-stage biotechnology company dedicated to transforming the treatment paradigm for hematological malignancies. Its lead candidate, LYT-200, is a first-in-class, mutation-agnostic antibody in development for the treatment of relapsed/refractory (R/R) high-risk myelodysplastic syndromes (HR-MDS). Gallop Oncology was founded by and is currently wholly owned by PureTech Health plc (LSE: PRTC). For more information, please visit www.galloponcology.com.

About PureTech Health

PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.

Prompts

PureTech Health plc (ticker PRTC), listed in United Kingdom.

ETFs Holding PureTech Health plc

ETF Weight in ETF Shares Market value As of
AVDS 0.01% 25,218 $ 39.118K Nov 16, 2026
AVDE 0.00% 260,887 $ 404.691K Nov 16, 2026